

# Justin R Gregg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4240510/publications.pdf>

Version: 2024-02-01

20  
papers

208  
citations

1307594

7  
h-index

1058476

14  
g-index

23  
all docs

23  
docs citations

23  
times ranked

437  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. <i>Nature Communications</i> , 2020, 11, 4279.	12.8	52
2	Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 168-184.	27.6	41
3	Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. <i>European Urology</i> , 2018, 74, 140-143.	1.9	16
4	Considering the potential for gene-based therapy in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 170-184.	3.8	13
5	Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. <i>BJU International</i> , 2021, 127, 340-348.	2.5	12
6	Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. <i>Journal of Urology</i> , 2019, 201, 308-314.	0.4	10
7	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
8	Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. <i>British Journal of Cancer</i> , 2019, 120, 466-471.	6.4	8
9	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. <i>Oncolmmunology</i> , 2019, 8, e1483303.	4.6	7
10	Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. <i>BJUI Compass</i> , 2021, 2, 188-193.	1.3	7
11	Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. <i>Cancer</i> , 2021, 127, 720-728.	4.1	7
12	Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. <i>Urology</i> , 2020, 138, 91-97.	1.0	6
13	Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. <i>World Journal of Urology</i> , 2021, 39, 3259-3264.	2.2	5
14	Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. <i>European Urology Focus</i> , 2021, 7, 71-77.	3.1	3
15	COMPLICATIONS OF PERI-OPERATIVE URETERAL CATHETER PLACEMENT: EXPERIENCE AT A MAJOR CANCER CENTER. <i>Urology</i> , 2021, , .	1.0	3
16	Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. <i>BJUI Compass</i> , 2022, 3, 68-74.	1.3	3
17	Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy. <i>BJU International</i> , 2021, 127, 524-527.	2.5	2
18	Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. <i>Urology</i> , 2021, 155, 144-151.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Study protocol: One plus one can be greater than two—Ecological momentary assessment for Black prostate cancer survivors and partners. PLoS ONE, 2021, 16, e0255614.	2.5	1
20	Editorial Comment. Journal of Urology, 2020, 204, 245-246.	0.4	0